Loading…

Adherence to the National Quality Forum (NQF) Breast Cancer Measures Within Cancer Clinical Trials: A Review From ACOSOG Z0010

Background In 2007, the National Quality Forum (NQF) released four performance measures for the treatment of breast cancer. We proposed to study the degree of adherence with these measures among participating institutions in a multi-institutional trial. Methods American College of Surgeons Oncology...

Full description

Saved in:
Bibliographic Details
Published in:Annals of surgical oncology 2010-08, Vol.17 (8), p.1989-1994
Main Authors: Wilke, Lee G., Ballman, Karla V., McCall, Linda M., Giuliano, Armando E., Whitworth, Pat W., Blumencranz, Peter W., Reintgen, Douglas S., Burak, William E., Leitch, A. Marilyn, Hunt, Kelly K.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c468t-e245b93e4160091415fc7cdee20808c25d101e98a061b79cb185f3f3a71b26173
cites cdi_FETCH-LOGICAL-c468t-e245b93e4160091415fc7cdee20808c25d101e98a061b79cb185f3f3a71b26173
container_end_page 1994
container_issue 8
container_start_page 1989
container_title Annals of surgical oncology
container_volume 17
creator Wilke, Lee G.
Ballman, Karla V.
McCall, Linda M.
Giuliano, Armando E.
Whitworth, Pat W.
Blumencranz, Peter W.
Reintgen, Douglas S.
Burak, William E.
Leitch, A. Marilyn
Hunt, Kelly K.
description Background In 2007, the National Quality Forum (NQF) released four performance measures for the treatment of breast cancer. We proposed to study the degree of adherence with these measures among participating institutions in a multi-institutional trial. Methods American College of Surgeons Oncology Group (ACOSOG) Z0010 enrolled breast cancer patients onto a phase II trial studying the prognostic significance of bone marrow and sentinel node micrometastases. The current study used χ 2 analyses to determine the degree of adherence with four NQF measures among three institution types: academic, community, and teaching affiliate. Results The study revealed small but important differences in two measures. Ninety-five percent of patients from teaching affiliated institutions received whole-breast radiation compared to 92% at academic and 91% at community hospitals. Among patients who were underinsured or uninsured, a marked decrease in radiation use was noted in comparison to patients with insurance—85 versus 93%, respectively. The study also revealed a difference among institutional types in patients undergoing excisional biopsy for diagnosis. In teaching-affiliated hospitals, 28.6% underwent excisional biopsy as compared to 36.8 and 37.4% in academic and community hospitals, respectively. There was no statistically significant difference between adherence rates with the remaining two measures. Adjuvant chemotherapy was administered to patients with hormone receptor negative tumors ≥1 cm in size in 79–85% of institutions. Tamoxifen was administered to 79–82% of those patients with hormone receptor–positive cancers. Conclusions Among breast cancer patients enrolled onto a multi-institutional clinical trial, we found a high degree of adherence with current consensus standards for adjuvant treatment, despite varied practice environments.
doi_str_mv 10.1245/s10434-010-0980-9
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2950006</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2079905211</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-e245b93e4160091415fc7cdee20808c25d101e98a061b79cb185f3f3a71b26173</originalsourceid><addsrcrecordid>eNp1UcFu1DAQtRCIlsIHcEEWJzgEZpLYiTkgLRFbkEpXhSIkLpbjnXRdZeNiO0W98O242rbAgZPtmffezPNj7CnCKyxr8Toi1FVdAEIBqoVC3WP7KHKlli3ez3eQbaFKKfbYoxjPAbCpQDxkeyVUoGQN--zXYr2hQJMlnjxPG-LHJjk_mZGfzGZ06YovfZi3_MXxyfIlfxfIxMQ7kwmBf8qPOVDk31zauOm23I1ucjYrnAZnxviGL_hnunT0ky-D3_JFt_qyOuTf8zrwmD0YMoSe3JwH7Ovy_Wn3oThaHX7sFkeFzVZSQdltryqqUQIorFEMtrFrohJaaG0p1ghIqjUgsW-U7bEVQzVUpsG-lNn1AXu7072Y-y2tLU0pmFFfBLc14Up74_S_nclt9Jm_1KUSACCzwPMbgeB_zBSTPvdzyN8UtQRV1VUjRQbhDmSDjzHQcDcAQV8npneJ6excXyemVeY8-3uzO8ZtRBlQ7gAxt6YzCn8m_1_1N_3Knxw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>609343765</pqid></control><display><type>article</type><title>Adherence to the National Quality Forum (NQF) Breast Cancer Measures Within Cancer Clinical Trials: A Review From ACOSOG Z0010</title><source>Springer Link</source><creator>Wilke, Lee G. ; Ballman, Karla V. ; McCall, Linda M. ; Giuliano, Armando E. ; Whitworth, Pat W. ; Blumencranz, Peter W. ; Reintgen, Douglas S. ; Burak, William E. ; Leitch, A. Marilyn ; Hunt, Kelly K.</creator><creatorcontrib>Wilke, Lee G. ; Ballman, Karla V. ; McCall, Linda M. ; Giuliano, Armando E. ; Whitworth, Pat W. ; Blumencranz, Peter W. ; Reintgen, Douglas S. ; Burak, William E. ; Leitch, A. Marilyn ; Hunt, Kelly K.</creatorcontrib><description>Background In 2007, the National Quality Forum (NQF) released four performance measures for the treatment of breast cancer. We proposed to study the degree of adherence with these measures among participating institutions in a multi-institutional trial. Methods American College of Surgeons Oncology Group (ACOSOG) Z0010 enrolled breast cancer patients onto a phase II trial studying the prognostic significance of bone marrow and sentinel node micrometastases. The current study used χ 2 analyses to determine the degree of adherence with four NQF measures among three institution types: academic, community, and teaching affiliate. Results The study revealed small but important differences in two measures. Ninety-five percent of patients from teaching affiliated institutions received whole-breast radiation compared to 92% at academic and 91% at community hospitals. Among patients who were underinsured or uninsured, a marked decrease in radiation use was noted in comparison to patients with insurance—85 versus 93%, respectively. The study also revealed a difference among institutional types in patients undergoing excisional biopsy for diagnosis. In teaching-affiliated hospitals, 28.6% underwent excisional biopsy as compared to 36.8 and 37.4% in academic and community hospitals, respectively. There was no statistically significant difference between adherence rates with the remaining two measures. Adjuvant chemotherapy was administered to patients with hormone receptor negative tumors ≥1 cm in size in 79–85% of institutions. Tamoxifen was administered to 79–82% of those patients with hormone receptor–positive cancers. Conclusions Among breast cancer patients enrolled onto a multi-institutional clinical trial, we found a high degree of adherence with current consensus standards for adjuvant treatment, despite varied practice environments.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1245/s10434-010-0980-9</identifier><identifier>PMID: 20309640</identifier><language>eng</language><publisher>New York: Springer-Verlag</publisher><subject>Academic Medical Centers - standards ; Adult ; Aged ; Bone Marrow Neoplasms - secondary ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Cancer Care Facilities - standards ; Chi-Square Distribution ; Clinical Trials, Phase II as Topic - standards ; Female ; Guideline Adherence ; Healthcare Policy and Outcomes ; Hospitals, Teaching - standards ; Humans ; Lymph Nodes - pathology ; Lymphatic Metastasis ; Medicine ; Medicine &amp; Public Health ; Middle Aged ; Multicenter Studies as Topic ; Oncology ; Practice Guidelines as Topic ; Prognosis ; Prospective Studies ; Societies, Medical ; Surgery ; Surgical Oncology ; United States</subject><ispartof>Annals of surgical oncology, 2010-08, Vol.17 (8), p.1989-1994</ispartof><rights>Society of Surgical Oncology 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-e245b93e4160091415fc7cdee20808c25d101e98a061b79cb185f3f3a71b26173</citedby><cites>FETCH-LOGICAL-c468t-e245b93e4160091415fc7cdee20808c25d101e98a061b79cb185f3f3a71b26173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20309640$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wilke, Lee G.</creatorcontrib><creatorcontrib>Ballman, Karla V.</creatorcontrib><creatorcontrib>McCall, Linda M.</creatorcontrib><creatorcontrib>Giuliano, Armando E.</creatorcontrib><creatorcontrib>Whitworth, Pat W.</creatorcontrib><creatorcontrib>Blumencranz, Peter W.</creatorcontrib><creatorcontrib>Reintgen, Douglas S.</creatorcontrib><creatorcontrib>Burak, William E.</creatorcontrib><creatorcontrib>Leitch, A. Marilyn</creatorcontrib><creatorcontrib>Hunt, Kelly K.</creatorcontrib><title>Adherence to the National Quality Forum (NQF) Breast Cancer Measures Within Cancer Clinical Trials: A Review From ACOSOG Z0010</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><addtitle>Ann Surg Oncol</addtitle><description>Background In 2007, the National Quality Forum (NQF) released four performance measures for the treatment of breast cancer. We proposed to study the degree of adherence with these measures among participating institutions in a multi-institutional trial. Methods American College of Surgeons Oncology Group (ACOSOG) Z0010 enrolled breast cancer patients onto a phase II trial studying the prognostic significance of bone marrow and sentinel node micrometastases. The current study used χ 2 analyses to determine the degree of adherence with four NQF measures among three institution types: academic, community, and teaching affiliate. Results The study revealed small but important differences in two measures. Ninety-five percent of patients from teaching affiliated institutions received whole-breast radiation compared to 92% at academic and 91% at community hospitals. Among patients who were underinsured or uninsured, a marked decrease in radiation use was noted in comparison to patients with insurance—85 versus 93%, respectively. The study also revealed a difference among institutional types in patients undergoing excisional biopsy for diagnosis. In teaching-affiliated hospitals, 28.6% underwent excisional biopsy as compared to 36.8 and 37.4% in academic and community hospitals, respectively. There was no statistically significant difference between adherence rates with the remaining two measures. Adjuvant chemotherapy was administered to patients with hormone receptor negative tumors ≥1 cm in size in 79–85% of institutions. Tamoxifen was administered to 79–82% of those patients with hormone receptor–positive cancers. Conclusions Among breast cancer patients enrolled onto a multi-institutional clinical trial, we found a high degree of adherence with current consensus standards for adjuvant treatment, despite varied practice environments.</description><subject>Academic Medical Centers - standards</subject><subject>Adult</subject><subject>Aged</subject><subject>Bone Marrow Neoplasms - secondary</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Cancer Care Facilities - standards</subject><subject>Chi-Square Distribution</subject><subject>Clinical Trials, Phase II as Topic - standards</subject><subject>Female</subject><subject>Guideline Adherence</subject><subject>Healthcare Policy and Outcomes</subject><subject>Hospitals, Teaching - standards</subject><subject>Humans</subject><subject>Lymph Nodes - pathology</subject><subject>Lymphatic Metastasis</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Middle Aged</subject><subject>Multicenter Studies as Topic</subject><subject>Oncology</subject><subject>Practice Guidelines as Topic</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Societies, Medical</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>United States</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNp1UcFu1DAQtRCIlsIHcEEWJzgEZpLYiTkgLRFbkEpXhSIkLpbjnXRdZeNiO0W98O242rbAgZPtmffezPNj7CnCKyxr8Toi1FVdAEIBqoVC3WP7KHKlli3ez3eQbaFKKfbYoxjPAbCpQDxkeyVUoGQN--zXYr2hQJMlnjxPG-LHJjk_mZGfzGZ06YovfZi3_MXxyfIlfxfIxMQ7kwmBf8qPOVDk31zauOm23I1ucjYrnAZnxviGL_hnunT0ky-D3_JFt_qyOuTf8zrwmD0YMoSe3JwH7Ovy_Wn3oThaHX7sFkeFzVZSQdltryqqUQIorFEMtrFrohJaaG0p1ghIqjUgsW-U7bEVQzVUpsG-lNn1AXu7072Y-y2tLU0pmFFfBLc14Up74_S_nclt9Jm_1KUSACCzwPMbgeB_zBSTPvdzyN8UtQRV1VUjRQbhDmSDjzHQcDcAQV8npneJ6excXyemVeY8-3uzO8ZtRBlQ7gAxt6YzCn8m_1_1N_3Knxw</recordid><startdate>20100801</startdate><enddate>20100801</enddate><creator>Wilke, Lee G.</creator><creator>Ballman, Karla V.</creator><creator>McCall, Linda M.</creator><creator>Giuliano, Armando E.</creator><creator>Whitworth, Pat W.</creator><creator>Blumencranz, Peter W.</creator><creator>Reintgen, Douglas S.</creator><creator>Burak, William E.</creator><creator>Leitch, A. Marilyn</creator><creator>Hunt, Kelly K.</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20100801</creationdate><title>Adherence to the National Quality Forum (NQF) Breast Cancer Measures Within Cancer Clinical Trials: A Review From ACOSOG Z0010</title><author>Wilke, Lee G. ; Ballman, Karla V. ; McCall, Linda M. ; Giuliano, Armando E. ; Whitworth, Pat W. ; Blumencranz, Peter W. ; Reintgen, Douglas S. ; Burak, William E. ; Leitch, A. Marilyn ; Hunt, Kelly K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-e245b93e4160091415fc7cdee20808c25d101e98a061b79cb185f3f3a71b26173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Academic Medical Centers - standards</topic><topic>Adult</topic><topic>Aged</topic><topic>Bone Marrow Neoplasms - secondary</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Cancer Care Facilities - standards</topic><topic>Chi-Square Distribution</topic><topic>Clinical Trials, Phase II as Topic - standards</topic><topic>Female</topic><topic>Guideline Adherence</topic><topic>Healthcare Policy and Outcomes</topic><topic>Hospitals, Teaching - standards</topic><topic>Humans</topic><topic>Lymph Nodes - pathology</topic><topic>Lymphatic Metastasis</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Middle Aged</topic><topic>Multicenter Studies as Topic</topic><topic>Oncology</topic><topic>Practice Guidelines as Topic</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Societies, Medical</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wilke, Lee G.</creatorcontrib><creatorcontrib>Ballman, Karla V.</creatorcontrib><creatorcontrib>McCall, Linda M.</creatorcontrib><creatorcontrib>Giuliano, Armando E.</creatorcontrib><creatorcontrib>Whitworth, Pat W.</creatorcontrib><creatorcontrib>Blumencranz, Peter W.</creatorcontrib><creatorcontrib>Reintgen, Douglas S.</creatorcontrib><creatorcontrib>Burak, William E.</creatorcontrib><creatorcontrib>Leitch, A. Marilyn</creatorcontrib><creatorcontrib>Hunt, Kelly K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wilke, Lee G.</au><au>Ballman, Karla V.</au><au>McCall, Linda M.</au><au>Giuliano, Armando E.</au><au>Whitworth, Pat W.</au><au>Blumencranz, Peter W.</au><au>Reintgen, Douglas S.</au><au>Burak, William E.</au><au>Leitch, A. Marilyn</au><au>Hunt, Kelly K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adherence to the National Quality Forum (NQF) Breast Cancer Measures Within Cancer Clinical Trials: A Review From ACOSOG Z0010</atitle><jtitle>Annals of surgical oncology</jtitle><stitle>Ann Surg Oncol</stitle><addtitle>Ann Surg Oncol</addtitle><date>2010-08-01</date><risdate>2010</risdate><volume>17</volume><issue>8</issue><spage>1989</spage><epage>1994</epage><pages>1989-1994</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>Background In 2007, the National Quality Forum (NQF) released four performance measures for the treatment of breast cancer. We proposed to study the degree of adherence with these measures among participating institutions in a multi-institutional trial. Methods American College of Surgeons Oncology Group (ACOSOG) Z0010 enrolled breast cancer patients onto a phase II trial studying the prognostic significance of bone marrow and sentinel node micrometastases. The current study used χ 2 analyses to determine the degree of adherence with four NQF measures among three institution types: academic, community, and teaching affiliate. Results The study revealed small but important differences in two measures. Ninety-five percent of patients from teaching affiliated institutions received whole-breast radiation compared to 92% at academic and 91% at community hospitals. Among patients who were underinsured or uninsured, a marked decrease in radiation use was noted in comparison to patients with insurance—85 versus 93%, respectively. The study also revealed a difference among institutional types in patients undergoing excisional biopsy for diagnosis. In teaching-affiliated hospitals, 28.6% underwent excisional biopsy as compared to 36.8 and 37.4% in academic and community hospitals, respectively. There was no statistically significant difference between adherence rates with the remaining two measures. Adjuvant chemotherapy was administered to patients with hormone receptor negative tumors ≥1 cm in size in 79–85% of institutions. Tamoxifen was administered to 79–82% of those patients with hormone receptor–positive cancers. Conclusions Among breast cancer patients enrolled onto a multi-institutional clinical trial, we found a high degree of adherence with current consensus standards for adjuvant treatment, despite varied practice environments.</abstract><cop>New York</cop><pub>Springer-Verlag</pub><pmid>20309640</pmid><doi>10.1245/s10434-010-0980-9</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1068-9265
ispartof Annals of surgical oncology, 2010-08, Vol.17 (8), p.1989-1994
issn 1068-9265
1534-4681
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2950006
source Springer Link
subjects Academic Medical Centers - standards
Adult
Aged
Bone Marrow Neoplasms - secondary
Breast Neoplasms - pathology
Breast Neoplasms - therapy
Cancer Care Facilities - standards
Chi-Square Distribution
Clinical Trials, Phase II as Topic - standards
Female
Guideline Adherence
Healthcare Policy and Outcomes
Hospitals, Teaching - standards
Humans
Lymph Nodes - pathology
Lymphatic Metastasis
Medicine
Medicine & Public Health
Middle Aged
Multicenter Studies as Topic
Oncology
Practice Guidelines as Topic
Prognosis
Prospective Studies
Societies, Medical
Surgery
Surgical Oncology
United States
title Adherence to the National Quality Forum (NQF) Breast Cancer Measures Within Cancer Clinical Trials: A Review From ACOSOG Z0010
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T17%3A27%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adherence%20to%20the%20National%20Quality%20Forum%20(NQF)%20Breast%20Cancer%20Measures%20Within%20Cancer%20Clinical%20Trials:%20A%20Review%20From%20ACOSOG%20Z0010&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Wilke,%20Lee%20G.&rft.date=2010-08-01&rft.volume=17&rft.issue=8&rft.spage=1989&rft.epage=1994&rft.pages=1989-1994&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1245/s10434-010-0980-9&rft_dat=%3Cproquest_pubme%3E2079905211%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c468t-e245b93e4160091415fc7cdee20808c25d101e98a061b79cb185f3f3a71b26173%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=609343765&rft_id=info:pmid/20309640&rfr_iscdi=true